STAT

JUNE 10, 2024

… Moderna announced that, in a Phase 3 clinical trial, its combination Covid-19 and influenza vaccine generated stronger immune responses in older adults than individual vaccines targeting those viruses , STAT says. A combo shot could improve uptake of both flu and Covid vaccines.

Vaccines 257

Vaccines Immunity Immunization 257

STAT

OCTOBER 11, 2023

A company that Pfizer blamed for problems with a clinical trial testing a Lyme vaccine claims that regulators gave its procedures a clean bill of health during a recent inspection. Care Access served as a contract research organization and had enrolled about 3,000 patients in the late-stage trial.

Vaccines 279

Vaccines 279

STAT

SEPTEMBER 7, 2023

… South Africa was “bullied” into one-sided deals with Covid-19 vaccine suppliers, STAT reports. Vaccine contracts disclosed after a court case between the advocacy group Health Justice Initiative and the South African government showed the country often paid more than other groups for shots. Or something.

Vaccines 220

Vaccines 220

Express Pharma

AUGUST 22, 2024

The US Food and Drug Administration approved and granted emergency use authorisation (EUA) for updated mRNA COVID-19 vaccines (2024-2025 formula) to include a monovalent (single) component that corresponds to the Omicron variant KP.2 Today’s actions relate to updated mRNA COVID-19 vaccines manufactured by ModernaTX and Pfizer.

Vaccines 105

Vaccines 105

pharmaphorum

FEBRUARY 27, 2025

An FDA advisory committee due to be held in March to discuss the formulation of influenza vaccines for the 2025/26 flu season has been cancelled.

Vaccines 110

Vaccines 110

European Pharmaceutical Review

DECEMBER 22, 2022

has finalised a strategic partnership with the UK government to establish a state-of-the-art mRNA vaccine research, development, and manufacturing facility in the UK. It also has potential to develop vaccines for other respiratory diseases, such as flu and respiratory syncytial virus. Moderna, Inc.

Vaccines 131

Vaccines 131

Express Pharma

JANUARY 26, 2025

On January 23, 2025, Raja Bhanu, Director General of PHARMEXCIL along with the AVPS Chakravarthi, Honorary Advisor, Pharmexcil, met Aref Ali Alnuaimi, Consul General, UAE, in Hyderabad. Arab Health 2025 provides an excellent platform to demonstrate Indias capabilities and explore mutually beneficial opportunities in the UAE and beyond.

Pharmaceutical Manufacturing 82

Pharmaceutical Manufacturing Pharmaceutical Companies Pharmaceutical Companies Vaccines 82

Express Pharma

MARCH 5, 2025

As part of the ongoing Belgian economic mission to India, a titled Innovation for a Healthier World: Uniting Strengths from India and Belgium was held on March 5, 2025, at the Veermata Jijabai Botanical Udyan and Zoo in Mumbai. GSK contributes to more robust, long-term vaccine access worldwide.

Vaccines 80

Vaccines Hospitals 80

Express Pharma

JANUARY 22, 2025

The award was presented during a ceremony at Hotel Ritz Carlton, Pune, on January 21, 2025, in the presence of Chief Guest Dr R A Mashelkar, a scientist and Padma Vibhushan awardee. We took a significant personal and financial risk to ensure the vaccine’s safety and efficacy, even taking early doses ourselves before licensure.

Vaccines 109

Vaccines Pharmaceutical Companies Pharmaceutical Companies 109

pharmaphorum

DECEMBER 22, 2022

Construction will start early next year of a new manufacturing centre in the UK with the capacity to produce 250 million vaccine doses per year, the centrepiece of a 10-year alliance between the government and US biotech Moderna. The first vaccines are due to be produced at the new facility in 2025.

Vaccines 122

Vaccines 122

pharmaphorum

MARCH 14, 2025

The FDA has released its recommendations on the composition of influenza vaccines for the 2025-26 season, without the input of its external advisors

Vaccines 80

Vaccines 80

Express Pharma

JUNE 26, 2024

The success of the COVID-19 mRNA vaccines highlighted the major advantages of utilising mRNA technology in vaccine development. Consequently, the FDA has awarded a rising number of review designations to mRNA vaccines in recent years. Implementation of these vaccines is estimated to have prevented 14.4

Vaccines 111

Vaccines Immunity Immunization 111

Pharmaceutical Business Review

AUGUST 14, 2024

The vaccine candidate is a virus-like particle (VLP)-based, adjuvanted vaccine designed for active immunisation against chikungunya virus (CHIKV) infection. The US regulator will make a decision on the vaccine approval under the Prescription Drug User Fee Act (PDUFA) by 14 February 2025.

Vaccines 105

Vaccines 105

Express Pharma

JANUARY 3, 2025

Innovation must remain at the core of our efforts Kiran Mazumdar-Shaw, Chairperson, Biocon and Biocon Biologics Indias biopharma sector, currently valued at over $54 billion, is on a promising trajectory, and projected to reach nearly $63 billion by 2025. Serum Institute of India (SII) is the worlds largest vaccine manufacturer.

Biosimilars 105

Biosimilars Vaccines Hospitals Drug Development 105

Express Pharma

JANUARY 22, 2024

Cameroon has kickstarted the world’s first routine vaccine programme against malaria. It is one of 20 African countries planning to introduce the drug this year, according to global vaccine alliance Gavi. The vaccine is designed to be administered to young children in four doses from around five months of age.

Vaccines 105

Vaccines 105

pharmaphorum

FEBRUARY 1, 2021

The diplomatic row that broke out last week over the supply of AstraZeneca’s vaccine to Europe appears to have cooled after the UK pharma agreed to supply an extra nine million doses. Step forward on vaccines. The post AstraZeneca to supply nine million more vaccines to EU appeared first on.

Vaccines 115

Vaccines 115

Pharmaceutical Business Review

SEPTEMBER 6, 2024

This recommendation will aid in the potential authorisation of the vaccine for use in individuals aged six months and older to prevent Covid-19 in the upcoming 2024-2025 autumn/winter season. 1 family of Omicron subvariants for the upcoming vaccination campaign. Moderna’s vaccine targeting the JN.1

Vaccines 104

Vaccines 104

Express Pharma

JANUARY 6, 2025

In a recent GlobalDatas survey, The State of the Biopharmaceutical Industry 2025, the largest proportion (41 per cent) of surveyed pharmaceutical industry professionals indicated that the immuno-oncology/ cancer therapeutics present the strongest innovation pipeline in the next five years.

Vaccines 97

Vaccines 97

pharmaphorum

DECEMBER 1, 2021

Sanofi has added to its vaccine pipeline with an agreement to acquire Austria’s Origimm Biotechnology and its vaccine-based immunotherapy for people with acne. It will highlight vaccines for pneumococcal disease, meningitis, respiratory syncytial virus (RSV), influenza, and chlamydia. Photo by Scott Webb on Unsplash.

Vaccines 105

Vaccines 105

European Pharmaceutical Review

OCTOBER 6, 2023

Positive interim results from Moderna’s Phase I/II trial of mRNA-1083 , an investigational vaccine designed to immunise against both influenza and COVID-19, have been released. There are several benefits of the combination vaccine as a preventative measure against these respiratory conditions, according to the pharmaceutical company.

Vaccines 105

Vaccines Pharmaceutical Companies Pharmaceutical Companies 105

BioPharma Dive

JANUARY 13, 2025

The company lost more than $3 billion in market value after cutting its forecast for 2025 revenue from its COVID-19 and RSV vaccines.

Vaccines 124

Vaccines 124

BioPharma Dive

JUNE 10, 2024

Positive results from the trial could position Moderna to bring the two-in-one vaccine to market in 2025.

Vaccines 119

Vaccines 119

European Pharmaceutical Review

DECEMBER 19, 2023

Many of today’s vaccines are produced in ready-to-inject liquid formulations that must be kept cold to maintain stability. However, this greatly complicates both the worldwide distribution and stockpiling of vaccines and other drugs. A requisite cold chain has been designed and implemented to be uninterrupted from factory to patient.

Vaccines 111

Vaccines Communication Immunization Immunity 111

Express Pharma

OCTOBER 25, 2023

With influenza season well underway, vaccination campaigns are in full force in the northern hemisphere. This will reshape the global influenza vaccine market for the upcoming seasons, says GlobalData. Kurdach continues, “When the actual composition of vaccines will revert to trivalent formulations remains another question.

Vaccines 98

Vaccines 98

pharmaphorum

FEBRUARY 17, 2025

GSK joins arch-rival Pfizer in the market for five-in-one meningococcal vaccines with FDA approval for Penmenvy, a top launch prospect for 2025.

Vaccines 75

Vaccines 75

European Pharmaceutical Review

SEPTEMBER 28, 2023

There has been a steady stream of developments in the vaccine manufacturing space throughout 2023. A notable milestone was Moderna’s announcement in April that it had, following finalisation of a ten-year strategic partnership with the UK Government, commenced construction of its mRNA vaccine manufacturing technology centre.

Vaccines 98

Vaccines Pharmaceutical Manufacturing 98

European Pharmaceutical Review

MARCH 6, 2023

” Post-construction, the facility “will harness mRNA science that aims to develop and deliver innovative vaccines to the UK public that address emerging threats from respiratory viruses.” The Moderna Innovation and Technology Centre is expected to become operational in 2025.

Vaccines 98

Vaccines 98

Express Pharma

JUNE 3, 2024

mRESVIA is Moderna’s second approved product and reportedly the only RSV vaccine available in single-dose pre-filled syringes Moderna, announced that the U.S. This approval is also the first time an mRNA vaccine has been approved for a disease other than COVID-19. The primary analysis with 3.7 per cent (95.88 per cent CI 66.0

Vaccines 81

Vaccines Adverse Reactions Packaging 81

BioPharma Dive

OCTOBER 4, 2023

The company is planning to start a Phase 3 trial of the vaccine this year, and is targeting a regulatory approval in 2025.

Vaccines 112

Vaccines 112

Pharmacy Times

APRIL 2, 2025

The only major change is in the included strain of influenza A/H2N2 virus, which has been updated for both the egg-based and the cell- and recombinant-based vaccines.

Vaccines 49

Vaccines 49

European Pharmaceutical Review

FEBRUARY 4, 2025

[Moderna] was the biggest industry sponsor of clinical trials in the UK in 2023/24″ The site is anticipated to be fully operational later in 2025, ready to deliver British-made COVID-19 vaccines, ensuring a robust supply for the UK public, stated Darius Hughes, General Manager of Moderna UK.

Vaccines 71

Vaccines 71

pharmaphorum

SEPTEMBER 15, 2020

billion) order for up to 190 million doses of a coronavirus vaccine in development at French company Valneva. The new deal firms up an earlier agreement in principle with the UK in July that covered up to 100 million doses of VLA2001 , a purified inactivated SARS-CoV-2 vaccine that is expected to require a two-dose vaccination regimen.

Vaccines 80

Vaccines Immunity Immunization 80

pharmaphorum

MARCH 3, 2025

The "Deep Dive: Research and Development 2025" explores cheminformatics, vaccination history, and birth control. Plus 12 questions with Laura Starkie from UCB. Stay informed about the latest innovations and breakthroughs in these areas.

Vaccines 52

Vaccines 52

PharmaTech

AUGUST 22, 2024

The approvals and authorizations come amid a late summer surge in the virus that is tracking a bit earlier than the early fall wave in the US in 2023.

Vaccines 82

Vaccines 82

Big Molecule Watch

SEPTEMBER 3, 2024

On August 22, Moderna announced that FDA approved its supplemental Biologics License Application (“sBLA”) for a new formula of their COVID-19 vaccine, SPIKEVAX®, for individuals 12 years old and above. Emergency Use Authorization (“EUA”) was also granted for the updated vaccine for individuals aged 6 months to 11 years old.

Vaccines 59

Vaccines Hospitals 59

Pharmaceutical Business Review

SEPTEMBER 2, 2024

The Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) [NVX-CoV2705] is now authorised for active immunisation against Covid-19. Following the EUA, the vaccine is also recommended by the US Centers for Disease Control and Prevention (CDC). Our updated vaccine targets JN.1, 1.” “Our updated vaccine targets JN.1,

Vaccines 59

Vaccines Adverse Reactions Immunity Immunization 59

Pharmaceutical Technology

DECEMBER 21, 2022

This Moderna Innovation and Technology Centre (MITC) is expected to offer access to a locally produced future mRNA vaccine portfolio against respiratory viruses, subject to regulatory evaluation and licensure. Additionally, the centre is anticipated to have to capacity to make up to 250 million doses of vaccines per year.

Vaccines 140

Vaccines Communication 140